obesity

Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Yahoo/Zacks.com
Novo Nordisk
R&D
Kallyope
diabetes
obesity
Flag link:
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Endpoints
Rhythm Pharmaceuticals
R&D
obesity
Flag link:
Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety
Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety
CP Wire
microbiome
obesity
anxiety
depression
Flag link:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Novo Nordisk
obesity
semaglutide
Flag link:
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Endpoints
Novo Nordisk
obesity
semaglutide
Flag link:
Gelesis touts study of hydrogel obesity drug
Gelesis touts study of hydrogel obesity drug
Drug Delivery Business News
Gelesis
obesity
Gelesis100
Flag link:
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Endpoints
Rhythm Pharmaceuticals
IPOs
obesity
rare disease
Flag link:
Novo focuses on new obesity therapy Semaglutide
Novo focuses on new obesity therapy Semaglutide
GoInPharma
Novo Nordisk
obesity
semaglutide
Flag link:
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Reuters
Novo Nordisk
obesity
semaglutide
Flag link:
J&J unveils new obesity, arthritis collaborations, shares its molecule library
J&J unveils new obesity, arthritis collaborations, shares its molecule library
Fierce Biotech
JNJ
obesity
rheumatoid arthritis
molecules
molecule library
drug development
Flag link:
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1
Fierce Pharma
Novo Nordisk
Saxenda
Latin America
obesity
Flag link:
Zafgen starts comeback with first data on replacement weight loss drug
Zafgen starts comeback with first data on replacement weight loss drug
Fierce Biotech
Zafgen
obesity
beloranib
ZGN-1061
Flag link:
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Zafgen shares drop more than 40% as drug focus shifted
Zafgen shares drop more than 40% as drug focus shifted
Marketwatch
Zafgen
beloranib
ZGN-1061
obesity
Flag link:
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Marketwatch
Arena Pharmaceuticals
FDA
obesity
Eisai
Belviq XR
Flag link:
Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico
Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico
Seeking Alpha
Arena Pharmaceuticals
lorcaserin
obesity
Mexico
Flag link:
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Orexigen - Contrave Sales Present Troubling Data
Orexigen - Contrave Sales Present Troubling Data
Seeking Alpha
Orexigen
Contrave
obesity
Flag link:
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:

Pages